Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Flexner

Showing results (71-80 of 137) with videos related to

Pageof 14
Sort By:
Clinical Pharmacology and Therapeutics|May 7, 2003
Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitorsCarla B Washington, Charles Flexner, Lewis B Sheiner, et al.
AIDS (London, England)|May 11, 2018
The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?Marco Vitoria, Andrew Hill, Nathan Ford, et al.
American Journal of Physiology. Cell Physiology|April 13, 2004
Diarrhea-associated HIV-1 APIs potentiate muscarinic activation of Cl- secretion by T84 cells via prolongation of cytosolic Ca2+ signalingPaul A Rufo, Patricia W Lin, Adriana Andrade, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2010
Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211)Keith W Crawford, Chonghua Li, Anther Keung, et al.
Clinical Pharmacology and Therapeutics|March 7, 2003
Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutinFayez M Hamzeh, Constance Benson, John Gerber, et al.
AIDS Research and Human Retroviruses|June 22, 2010
Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavirKeith W Crawford, John Spritzler, Robert C Kalayjian, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 19, 2012
Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjectsKelly E Dooley, Patrick Sayre, Julie Borland, et al.
AIDS (London, England)|December 1, 2021
Impact of long-acting therapies on the global HIV epidemicNomathemba C Chandiwana, Celicia M Serenata, Andrew Owen, et al.
ACS Omega|July 21, 2025
Structure-Activity Relationship Studies of Emtricitabine Prodrugs toward Long-Acting Antiretroviral FormulationsAmer Al-Khouja, Stephanie Henriquez, James J Hobson, et al.
Antimicrobial Agents and Chemotherapy|July 13, 2011
Pharmacokinetic modeling of plasma and intracellular concentrations of raltegravir in healthy volunteersLingzhi Wang, Gaik Hong Soon, Kok-Yong Seng, et al.
Pageof 14

Showing results (71-80 of 137) with videos related to

Sort By:
Pageof 14
Clinical Pharmacology and Therapeutics|May 7, 2003
Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitorsCarla B Washington, Charles Flexner, Lewis B Sheiner, et al.
AIDS (London, England)|May 11, 2018
The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?Marco Vitoria, Andrew Hill, Nathan Ford, et al.
American Journal of Physiology. Cell Physiology|April 13, 2004
Diarrhea-associated HIV-1 APIs potentiate muscarinic activation of Cl- secretion by T84 cells via prolongation of cytosolic Ca2+ signalingPaul A Rufo, Patricia W Lin, Adriana Andrade, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2010
Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211)Keith W Crawford, Chonghua Li, Anther Keung, et al.
Clinical Pharmacology and Therapeutics|March 7, 2003
Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutinFayez M Hamzeh, Constance Benson, John Gerber, et al.
AIDS Research and Human Retroviruses|June 22, 2010
Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavirKeith W Crawford, John Spritzler, Robert C Kalayjian, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 19, 2012
Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjectsKelly E Dooley, Patrick Sayre, Julie Borland, et al.
AIDS (London, England)|December 1, 2021
Impact of long-acting therapies on the global HIV epidemicNomathemba C Chandiwana, Celicia M Serenata, Andrew Owen, et al.
ACS Omega|July 21, 2025
Structure-Activity Relationship Studies of Emtricitabine Prodrugs toward Long-Acting Antiretroviral FormulationsAmer Al-Khouja, Stephanie Henriquez, James J Hobson, et al.
Antimicrobial Agents and Chemotherapy|July 13, 2011
Pharmacokinetic modeling of plasma and intracellular concentrations of raltegravir in healthy volunteersLingzhi Wang, Gaik Hong Soon, Kok-Yong Seng, et al.
Pageof 14